Clinical Trial: Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients

U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06938659) titled 'Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients' on March 12.

Brief Summary: Low dose factor VIII prophylaxis is practiced around the world. Role of standard dose Emicizumab prophylaxis is well established. Emicizumab is an expensive drug. Standard dose Emicizumab prophylaxis is very expensive for hemophilia A patients and troublesome for government to ensure continuous supply. This study intends to compare low dose Factor VIII prophylaxis with low dose Emicizumab prophylaxis and compare whether low dose Emicizumab is as effective as low dose Factor VIII prophylaxis. So, it is possible to continu...